Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | UBE2M | P61081 | 1/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190839 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1POLBBCHEACHE | |
| SCHEMBL2190830 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1POLBBCHEACHE | |
| SCHEMBL2190734 | 0.91 | FUCA1 (0.58) | ALDH1A1BCHEACHEBACE1FUCA1 | |
| SCHEMBL12507213 | 0.91 | FUCA1 (0.58) | ALDH1A1BCHEACHEBACE1FUCA1 | |
| SCHEMBL2190740 | 0.91 | FUCA1 (0.58) | ALDH1A1BCHEACHEBACE1FUCA1 | |
| SCHEMBL2190729 | 0.91 | FUCA1 (0.58) | ALDH1A1BCHEACHEBACE1FUCA1 | |
| SCHEMBL2191712 | 0.89 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1POLBBCHEACHE | |
| SCHEMBL2191719 | 0.89 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1POLBBCHEACHE | |
| SCHEMBL2191725 | 0.89 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1POLBBCHEACHE | |
| SCHEMBL2191595 | 0.87 | DCUN1D1 (0.55) | ALDH1A1BCHEACHEBACE1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351738-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL | Sumitomo Chemical Company, Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | TEAD4, TEAD3, TEAD2 | SMN1; SMN2 4312/4885ALDH1A1 93/4885POLB 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.